Haemonetics Corp

Most Recent

  • uploads///medic _
    Earnings Report

    Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates

    Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Haemonetics

    Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why HAE’s Blood Center Business Could See Small Revenue Decline

    Haemonetics (HAE) expects its blood center business to report a year-over-year (or YoY) revenue decline in the range of 3% to 6% in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues

    Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Plasma Business Continues to Be Key Growth Driver for Haemonetics

    Haemonetics (HAE) expects its plasma franchise to report year-over-year (or YoY) revenue growth in the range of 7% to 10% in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Haemonetics Could Report Strong EPS Growth in Fiscal 2019

    In fiscal 2019, Haemonetics (HAE) expects to report adjusted earnings per share (or EPS) in the range of $2.0 to $2.3.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Haemonetics Is Expected to Report Modest Revenue Growth in Fiscal 2019

    In fiscal 2019, Haemonetics (HAE) expects to report year-over-year (or YoY) organic revenue growth in the range of 3% to 5% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Could Boost Haemonetics’ Revenues in Future Years

    Haemonetics (HAE) expects its transfusion management business to grow at compound annual growth rate (or CAGR) in the low to mid teens.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018

    Haemonetics (HAE) is currently the number one or number two player in the cell salvage segment in most of the geographies in which the company competes.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Hospital Business Remains 1of HAE’s Key Growth Drivers

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018

    Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Plasma Remains an Attractive Business for HAE

    In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018

    On its fiscal 3Q18 earnings conference call, Haemonetics increased the guidance for its fiscal 2018 adjusted EPS to the range $1.80–$1.90.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018

    Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017.

    By Margaret Patrick
  • uploads///blood _
    Company & Industry Overviews

    Analysts’ Recommendations for Haemonetics and Peers in March 2018

    In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.